PE20030119A1 - Derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6 - Google Patents

Derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6

Info

Publication number
PE20030119A1
PE20030119A1 PE2002000503A PE2002000503A PE20030119A1 PE 20030119 A1 PE20030119 A1 PE 20030119A1 PE 2002000503 A PE2002000503 A PE 2002000503A PE 2002000503 A PE2002000503 A PE 2002000503A PE 20030119 A1 PE20030119 A1 PE 20030119A1
Authority
PE
Peru
Prior art keywords
piperazin
indol
alkyl
benzenosulfonil
alcoxyl
Prior art date
Application number
PE2002000503A
Other languages
English (en)
Inventor
Andrew John Briggs
Robin Douglas Clark
Douglas Leslie Wren
David Bruce Repke
Ralph New Harris Iii
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20030119A1 publication Critical patent/PE20030119A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

SE REFIERE A DERIVADOS DE 4-PIPERAZINIL INDOL DE FORMULA I DONDE R1 ES H, HALO, HALOALQUILO, ALQUILO C1-C6; R2 ES H, ALQUILO C1-C6, ALCOXILO C1-C6, TIOALQUILO C1-C6; R3 ES SO2Ar; Ar ES ARILO, HETEROARILO OPCIONALMENTE SUSTITUIDO CON ALQUILO, ALCOXILO, TIOALQUILO, HALO, HALOALQUILO, HIDROXIALQUILO, NITRO, ENTRE OTROS; R4 ES H, HALOGENO, ALQUILO C1-C6, ALCOXILO C1-C6, TIOALQUILO C1-C6, TRIFLUOROMETILO, CIANO, ACILO; R5 ES H, BENCILO, ALQUILO C1-C6. SON COMPUESTOS PREFERIDOS 1-(NAFTALEN-1-SULFONIL)-4-PIPERAZIN-1-IL-1H-INDOL; 1-(3,5-DICLORO-BENCENOSULFONIL)-4-PIPERAZIN-1-IL-1H-INDOL; 1-BENCENOSULFONIL-4-PIPERAZIN-1-IL-1H-INDOL; 4-PIPERAZIN-1-IL-1-(3-TRIFLUOROMETIL-BENCENOSULFONIL)-1H-INDOL; 1-(4-METOXI-BENCENOSULFONIL)-4-PIPERAZIN-1-IL-1H-INDOL, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS SON AGONISTAS DEL RECEPTOR 5-HIDROXITRIPTAMINA 5-HT6 Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE ALZHEIMER, HUNTINGTON, PSICOSIS, ESQUIZOFRENIA, DEPRESIONES MANIACAS, TRASTORNOS DE DEFICIT DE ATENCION, ESCLEROSIS LATERAL AMIOTROFICA
PE2002000503A 2001-06-15 2002-06-12 Derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6 PE20030119A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29883401P 2001-06-15 2001-06-15
US37874802P 2002-05-08 2002-05-08

Publications (1)

Publication Number Publication Date
PE20030119A1 true PE20030119A1 (es) 2003-02-13

Family

ID=26970893

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000503A PE20030119A1 (es) 2001-06-15 2002-06-12 Derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6

Country Status (15)

Country Link
US (1) US6790848B2 (es)
EP (1) EP1401812B1 (es)
JP (1) JP2005501019A (es)
KR (1) KR20040010709A (es)
AR (1) AR036057A1 (es)
AT (1) ATE331707T1 (es)
BR (1) BR0210411A (es)
CA (1) CA2450245A1 (es)
DE (1) DE60212841T2 (es)
ES (1) ES2268113T3 (es)
MX (1) MXPA03011638A (es)
PA (1) PA8547901A1 (es)
PE (1) PE20030119A1 (es)
UY (1) UY27336A1 (es)
WO (1) WO2002102774A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001296193B2 (en) * 2000-10-20 2006-04-27 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-N1-(benzensulfonyl)indoles and their use in therapy
WO2003080580A2 (en) 2002-03-27 2003-10-02 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
KR100686758B1 (ko) * 2002-09-17 2007-02-26 에프. 호프만-라 로슈 아게 2,7-치환된 인돌 및 5-ｈｔ6 조절 인자로서의 그 용도
CN100395237C (zh) * 2003-03-03 2008-06-18 弗·哈夫曼-拉罗切有限公司 用作5－ht6调节剂的2,5－取代的四氢异喹啉
WO2004080407A2 (en) * 2003-03-07 2004-09-23 Predix Pharmaceuticals Holdings, Inc. New serotonin modulating compounds and uses therefor
JP2006525972A (ja) * 2003-05-09 2006-11-16 ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ 食物摂取障害の予防および／または治療用の医薬品製造のためのスルホンアミド誘導体の使用
ES2219181B1 (es) * 2003-05-09 2005-12-16 Laboratorios Del Dr. Esteve, S.A. Uso de derivados de sulfonamidas para la fabricacion de un medicamento para la profilaxis y/o tratamiento de las disfunciones alimentarias.
CN1826322B (zh) 2003-07-22 2012-04-18 艾尼纳制药公司 用于预防和治疗相关病症而作为5-ht2a血清素受体调节剂的二芳基和芳基杂芳基脲衍生物
JP4964593B2 (ja) * 2003-09-25 2012-07-04 セノメド バイオサイエンシーズ，エルエルシー 神経学的病状の治療用のテトラヒドロインドロン誘導体
SE0302760D0 (sv) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
KR100843053B1 (ko) * 2004-01-16 2008-07-01 에프. 호프만-라 로슈 아게 중추 신경계 질환의 치료를 위한 5-하이드록시트립트아민수용체(5-ｈｔ)의 조절제로서1-벤질-5-피페라진-1-일-3,4-다이하이드로-1ｈ-퀴나졸린-2-온 유도체 및 각각의1ｈ-벤조(1,2,6)티아다이아진-2,2-다이옥사이드 및1,4-다이하이드로-벤조(ｄ)(1,3)옥사진-2-온 유도체
US7713954B2 (en) * 2004-09-30 2010-05-11 Roche Palo Alto Llc Compositions and methods for treating cognitive disorders
CA2582273C (en) 2004-09-30 2013-10-29 Douglas William Bonhaus Compositions and methods for treating cognitive disorders using serotonin receptor antagonists
US9216966B2 (en) 2004-10-04 2015-12-22 John Manfredi Compounds for Alzheimer's disease
US7678823B2 (en) * 2004-10-04 2010-03-16 Myriad Pharmaceticals, Inc. Compounds for alzheimer's disease
US7696229B2 (en) * 2006-02-17 2010-04-13 Memory Pharmaceuticals Corporation Compounds having 5-HT6 receptor affinity
JP2009532501A (ja) * 2006-04-04 2009-09-10 ミリアド ジェネティクス， インコーポレイテッド 疾患および障害のための化合物
CA2655694C (en) 2006-07-03 2014-12-16 Biovitrum Ab (Publ) 1,4-substituted indoles useful for modulation of the 5-ht6 receptor
CA2668959A1 (en) * 2006-11-09 2008-05-15 F. Hoffmann-La Roche Ag Indole and benzofuran 2-carboxamide derivatives
US20080318941A1 (en) * 2007-05-24 2008-12-25 Memory Pharmaceuticals Corporation 4' substituted compounds having 5-ht6 receptor affinity
KR20100053626A (ko) * 2007-08-15 2010-05-20 메모리 파마슈티칼스 코포레이션 5-ｈｔ6 수용체 친화성을 나타내는 3'-치환된 화합물
WO2009062134A1 (en) * 2007-11-09 2009-05-14 Cenomed Biosciences, Llc Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperazine compounds
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
US20100016297A1 (en) * 2008-06-24 2010-01-21 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
US20100022581A1 (en) * 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
US20100029629A1 (en) * 2008-07-25 2010-02-04 Memory Pharmaceuticals Corporation Acyclic compounds having 5-ht6 receptor affinity
US20100056531A1 (en) * 2008-08-22 2010-03-04 Memory Pharmaceuticals Corporation Alkyl-substituted 3' compounds having 5-ht6 receptor affinity
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
UA100192C2 (en) 2008-11-11 2012-11-26 УАЙТ ЭлЭлСи 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands
US8367676B2 (en) 2009-06-30 2013-02-05 Astrazeneca Ab 2-carboxamide-7-piperazinyl-benzofuran derivatives 774
WO2011088836A1 (en) 2010-01-25 2011-07-28 H. Lundbeck A/S NOVEL 4-(ARYL-4-SULFONYL)-6,6a,7,8,9,10-HEXAHYDRO-4H-4,8,10a-TRIAZA-ACEPHENANTHRYLENE AND 3-ARYLSULFONYL-6,6a,7,8,9,10-HEXAHYDRO-3H-3,8,10a-TRIAZA-CYCLOPENTA[C]FLUORENE DERIVATIVES AS SEROTONIN 5-HT6 LIGANDS
US20120157494A1 (en) * 2010-12-16 2012-06-21 Harris Iii Ralph New Isoindolyl compounds
CN103380129B (zh) 2010-12-20 2016-04-20 阿克图拉姆生命科学股份公司 2-甲酰胺-4-哌嗪基-苯并呋喃衍生物
CN104725295B (zh) 2013-12-20 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
SG11201610407QA (en) 2014-07-08 2017-01-27 Sunshine Lake Pharma Co Ltd Aromatic heterocyclic derivatives and pharmaceutical applications thereof
AU2016276966A1 (en) 2015-06-12 2018-01-18 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of REM sleep behavior disorder
TW201720439A (zh) 2015-07-15 2017-06-16 Axovant Sciences Gmbh 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物
WO2017052394A1 (en) 2015-09-23 2017-03-30 Uniwersytet Jagielloński Imidazopyridine compounds and their use as 5-ht6 receptor ligands
EP3911651B1 (en) 2019-01-17 2024-01-10 ViiV Healthcare UK (No.4) Limited Process for preparing fostemsavir

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60190761A (ja) 1984-03-09 1985-09-28 Sagami Chem Res Center ４−アミノインド−ルの製造方法
WO1995006637A1 (en) * 1993-09-03 1995-03-09 Smithkline Beecham Plc Indole and indoline derivatives as 5ht1d receptor antagonists
WO1996003400A1 (en) 1994-07-26 1996-02-08 Pfizer Inc. 4-indole derivatives as serotonin agonists and antagonists
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US6251893B1 (en) 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
DE19934433A1 (de) * 1999-07-22 2001-01-25 Merck Patent Gmbh N-(Indolcarbonyl-)piperazinderivate
WO2001032660A1 (en) 1999-11-05 2001-05-10 Nps Allelix Corp. Compounds having 5-ht6 receptor antagonist activity
SE0002754D0 (sv) * 2000-07-21 2000-07-21 Pharmacia & Upjohn Ab New pharmaceutical combination formulation and method of treatment with the combination
AU2001296193B2 (en) * 2000-10-20 2006-04-27 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-N1-(benzensulfonyl)indoles and their use in therapy
KR100822655B1 (ko) * 2000-11-02 2008-04-17 와이어쓰 5-하이드록시트립타민-6 리간드로서의 1-아릴설포닐- 또는 1-알킬설포닐-헤테로사이클릴벤즈아졸, 이의 제조방법 및 이를 포함하는 약제학적 조성물
ES2271124T3 (es) * 2000-11-24 2007-04-16 Smithkline Beecham Plc Compuestos indolil-sulfonilicos utiles en el tratamiento de trastornos del snc.

Also Published As

Publication number Publication date
ES2268113T3 (es) 2007-03-16
DE60212841T2 (de) 2007-06-21
EP1401812B1 (en) 2006-06-28
US20030045527A1 (en) 2003-03-06
JP2005501019A (ja) 2005-01-13
DE60212841D1 (de) 2006-08-10
US6790848B2 (en) 2004-09-14
AR036057A1 (es) 2004-08-04
EP1401812A1 (en) 2004-03-31
UY27336A1 (es) 2002-12-31
WO2002102774A1 (en) 2002-12-27
CA2450245A1 (en) 2002-12-27
MXPA03011638A (es) 2004-04-02
KR20040010709A (ko) 2004-01-31
ATE331707T1 (de) 2006-07-15
PA8547901A1 (es) 2003-12-10
BR0210411A (pt) 2004-08-17

Similar Documents

Publication Publication Date Title
PE20030119A1 (es) Derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6
PE20040512A1 (es) Compuesto de pirazol-pirimidina anilina
PE20001583A1 (es) Derivados de la 1-arenosulfonil-2-arilo-pirrolidina y de la piperidina
PE20030039A1 (es) Derivados de indol con afinidad por el receptor 5-ht6
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20020103A1 (es) Derivados de 1-sulfonil-pirrolidina
PE20020338A1 (es) DERIVADOS DEL 3-INDOLIL-4-FENIL-1H-PIRROL-2,5-DIONA QUE INHIBEN LA GLUCOGENO SINTASA QUINASA-3ß (GSK-3ß)
HN2001000099A (es) Nuevos derivados del fenil-propargiileter
PE20061298A1 (es) Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
PE20051058A1 (es) Fenilalanina-amidas sustituidas por benzoilo
DE3868301D1 (de) 2-(methyl(4-piperidinyl))-1,2,3,4-tetrahydro-9h-pyrido(3,4-b)indolderivate, ihre herstellung und therapeutische verwendung.
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
PE20010574A1 (es) Derivados de indol como ligandos del receptor 5-ht2
PE20020915A1 (es) Diaminotiazoles como inhibidores de quinasas dependientes de ciclina
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
PE20020720A1 (es) Derivados benzimidazol y piridilimidazol como ligandos para receptores gabaa
RU96111002A (ru) 3-замещенные оксиндольные производные в качестве модуляторов калийных каналов, фармацевтическая композиция, способ лечения
PE20091005A1 (es) N-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas
PE68799A1 (es) Derivados de tetrahidroisoquinolina como moduladores del receptor de d3 de dopamina
PE20031011A1 (es) Derivados de dihidrobenzodiazepin-2-ona-iii
AR037288A1 (es) Compuestos derivados de sulfonamidas, procedimiento para la obtencion, composicion farmaceutica y uso para la elaboracion de un medicamento
PE20010068A1 (es) Compuestos derivados de piperidina como inhibidores de renina
PE20010641A1 (es) Derivados de piperazina como antagonistas del receptor de serotonina 5-ht1b
PE20070490A1 (es) Compuestos derivados de bencimidazol-2-ona sustituidos con piperidina como agonistas del receptor muscarinico m1
DE602004012858D1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten

Legal Events

Date Code Title Description
FD Application declared void or lapsed